Insider Selling: BioLife Solutions (NASDAQ:BLFS) Insider Sells 511 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Karen Foster sold 511 shares of the company’s stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $26.83, for a total value of $13,710.13. Following the completion of the transaction, the insider directly owned 193,672 shares in the company, valued at approximately $5,196,219.76. The trade was a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

BioLife Solutions Price Performance

NASDAQ BLFS opened at $25.80 on Tuesday. The stock’s fifty day moving average price is $23.55 and its 200 day moving average price is $23.30. BioLife Solutions, Inc. has a 1 year low of $19.10 and a 1 year high of $29.55. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -214.98 and a beta of 1.78.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.31). The company had revenue of $25.42 million for the quarter, compared to analyst estimates of $23.71 million. BioLife Solutions had a positive return on equity of 0.16% and a negative net margin of 5.39%. BioLife Solutions has set its FY 2025 guidance at EPS. Research analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on BLFS shares. Stephens started coverage on BioLife Solutions in a research report on Tuesday, July 22nd. They set an “overweight” rating and a $30.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target (up from $30.00) on shares of BioLife Solutions in a research report on Friday, August 8th. Wall Street Zen downgraded BioLife Solutions from a “hold” rating to a “sell” rating in a research report on Wednesday, May 21st. Finally, Zacks Research raised BioLife Solutions to a “strong-buy” rating in a research report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $31.29.

Institutional Investors Weigh In On BioLife Solutions

A number of institutional investors have recently modified their holdings of BLFS. Northern Trust Corp grew its position in shares of BioLife Solutions by 7.9% during the 4th quarter. Northern Trust Corp now owns 411,033 shares of the medical equipment provider’s stock valued at $10,670,000 after acquiring an additional 30,217 shares during the period. Deutsche Bank AG lifted its stake in BioLife Solutions by 49.8% in the 4th quarter. Deutsche Bank AG now owns 31,171 shares of the medical equipment provider’s stock valued at $809,000 after buying an additional 10,368 shares in the last quarter. Graham Capital Management L.P. purchased a new position in BioLife Solutions in the 4th quarter valued at about $254,000. Gotham Asset Management LLC lifted its stake in BioLife Solutions by 11.5% in the 4th quarter. Gotham Asset Management LLC now owns 13,800 shares of the medical equipment provider’s stock valued at $358,000 after buying an additional 1,426 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in BioLife Solutions by 5.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,508 shares of the medical equipment provider’s stock valued at $532,000 after buying an additional 1,047 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.